View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNanomix 배당 및 자사주 매입배당 기준 점검 0/6Nanomix 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 10Nanomix Corporation Common Stock Deleted from OTC EquityNanomix Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC.공시 • Nov 27Nanomix Corporation Announces Chief Executive Officer ChangesOn November 3, 2023 (the “Effective Date”), Nanomix Corporation appointed David Ludvigson as interim chief executive officer of the Company, effective immediately. Mr. Ludvigson succeeds Dr. Thomas Schlumpberger who unexpectedly passed away on November 2, 2023. Mr. Ludvigson served as chief executive officer of the Company from June 2021 to July 2022, chief financial officer from June 2021 until January 2023 and as a director since June 2021. From June 2013 to June 2021, he served as CEO of Nanomix Inc. From October 2009 through present day, Mr. Ludvigson has served as President of Knight Ludvigson Advisors providing advisory and business consulting services to Life Science and Technology companies including M&A, financing, business strategy, go to market planning and sales channel strategy and implementation. Mr. Ludvigson serves on the board of directors of Imagion Biosystems Inc., One BioMed PTE LTD (privately held), Incando Therapeutics Inc. (privately held) and China Stem Cells Ltd. (privately held). Mr. Ludvigson received his BS and MAS in Accounting from Gies College of Business – University of Illinois Urbana-Champaign.공시 • May 16Nanomix Corporation announced delayed 10-Q filingOn 05/15/2023, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 26Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial OfficerNanomix Corporation announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO). Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program.공시 • Sep 01+ 1 more updateNanomix Names Tadd S. Lazarus to Board of DirectorsNanomix Names Tadd S. Lazarus to Board of Directors.공시 • Jul 27+ 1 more updateNanomix Corporation Appoints Thomas Schlumpberger as Member of the Board of DirectorsNanomix Corporation announced the appointment of Dr. Thomas Schlumpberger as member of the Board of Directors, effective immediately. Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. His broad base of experience is directly applicable to the next phase of growth at Nanomix as the Company’s POC platform gains customer adoption. At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere. At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix. He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.공시 • Jun 23Nanomix Corporation Initiates New Clinical Study for the eLab S1 PanelNanomix Corporation announced that it has initiated a clinical validation study with Hospital Clinico San Carlos (HCSC) in Madrid, Spain to evaluate the performance of the Nanomix eLab® mobile immunoassay diagnostic system and the S1 Panel assay for the detection of critical infections such as sepsis in the emergency department. The principal investigator of the study is Dr. Juan González del Castillo, Internal Medicine Specialist, Assistant Physician of the Emergency Service of HCSC and Coordinator of the Infections Group of the Spanish Society of Emergency Medicine (SEMES). The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.공시 • Jun 15Nanomix Corporation Receives IVDR Certification for the eLab AnalyzerNanomix Corporation announced that it has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer, part of the Nanomix eLab® system. The European Union (EU) IVDR replaces the legacy In Vitro Diagnostic Directive (IVDD) and was created to ensure a greater level of patient protection and regulation around the creation of in vitro diagnostic devices (IVDs). The Nanomix eLab® system is a rapid, easy-to-use, quantitative detection platform that performs a range of in vitro diagnostic assays. The platform consists of a hand-held analyzer and a disposable cartridge. The eLab System utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. The Nanomix eLab® system has received the CE marking in Europe.공시 • May 27Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood SamplesNanomix Corporation announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample. The eLab S1 is currently marketed and CE marked for use with a plasma sample. The new authorization for a whole blood sample provides even faster results than the Company's earlier plasma-based panel by eliminating the step of first centrifuging blood to produce a plasma sample. Key Advantages: The ab b S1 assay panel is the first of its kind offering Procalcitonin(PCT), C-Reactive Protn (CRP) and LaLactate (LAC) for use on its testing device in emergency departments and decentralized healthcare environments,Faster time to results -- driving information within the initial clinical decision-making window,Increased accessibility and broader end-user market,Designed to help providers achieve better patient outcomes . The S1 Assay panel was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for LAC, CRP and PCT from a single plasma sample or venous whole blood sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The Nanomix eLab(R) system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab(R) offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. About Nanomix CorporationNanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nan mix eLab(R) System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company's products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix's first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.공시 • May 18Nanomix Corporation announced delayed 10-Q filingOn 05/17/2022, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Mar 31Nanomix Corporation Appoints Vidur Sahney as Chief Operating OfficerNanomix Corporation announced the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assay development and quality. Most recently, Mr. Sahney served as Chief Operating Officer of ExThera Medical where he led the initiative to secure U.S. Food and Drug Administration (FDA) Emergency Use Authorization site clearance and CE mark for a Class III /PMA medical device, and commercialized the novel hemoperfusion filter used to treat blood stream infections and COVID-19 in Europe and the U.S.공시 • Mar 30Nanomix Corporation announced delayed annual 10-K filingOn 03/29/2022, Nanomix Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Dec 09Nanomix Announces UK MHRA Registration for New Point of Care SystemNanomix Corporation announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge. The Nanomix eLab analyzer with S1 Panel Cartridge provides multiple host-response biomarker results that can assist healthcare providers in diagnosing and treating patients with critical infections, including sepsis.공시 • Dec 02Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19Nanomix Corporation announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments. The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes. The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy.공시 • Aug 17Boston Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NNMX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NNMX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Nanomix 배당 수익률 vs 시장NNMX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NNMX)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Medical Equipment)2.1%분석가 예측 (NNMX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NNMX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NNMX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NNMX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NNMX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/04/09 19:31종가2025/02/24 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nanomix Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 10Nanomix Corporation Common Stock Deleted from OTC EquityNanomix Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC.
공시 • Nov 27Nanomix Corporation Announces Chief Executive Officer ChangesOn November 3, 2023 (the “Effective Date”), Nanomix Corporation appointed David Ludvigson as interim chief executive officer of the Company, effective immediately. Mr. Ludvigson succeeds Dr. Thomas Schlumpberger who unexpectedly passed away on November 2, 2023. Mr. Ludvigson served as chief executive officer of the Company from June 2021 to July 2022, chief financial officer from June 2021 until January 2023 and as a director since June 2021. From June 2013 to June 2021, he served as CEO of Nanomix Inc. From October 2009 through present day, Mr. Ludvigson has served as President of Knight Ludvigson Advisors providing advisory and business consulting services to Life Science and Technology companies including M&A, financing, business strategy, go to market planning and sales channel strategy and implementation. Mr. Ludvigson serves on the board of directors of Imagion Biosystems Inc., One BioMed PTE LTD (privately held), Incando Therapeutics Inc. (privately held) and China Stem Cells Ltd. (privately held). Mr. Ludvigson received his BS and MAS in Accounting from Gies College of Business – University of Illinois Urbana-Champaign.
공시 • May 16Nanomix Corporation announced delayed 10-Q filingOn 05/15/2023, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 26Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial OfficerNanomix Corporation announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO). Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program.
공시 • Sep 01+ 1 more updateNanomix Names Tadd S. Lazarus to Board of DirectorsNanomix Names Tadd S. Lazarus to Board of Directors.
공시 • Jul 27+ 1 more updateNanomix Corporation Appoints Thomas Schlumpberger as Member of the Board of DirectorsNanomix Corporation announced the appointment of Dr. Thomas Schlumpberger as member of the Board of Directors, effective immediately. Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. His broad base of experience is directly applicable to the next phase of growth at Nanomix as the Company’s POC platform gains customer adoption. At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere. At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix. He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.
공시 • Jun 23Nanomix Corporation Initiates New Clinical Study for the eLab S1 PanelNanomix Corporation announced that it has initiated a clinical validation study with Hospital Clinico San Carlos (HCSC) in Madrid, Spain to evaluate the performance of the Nanomix eLab® mobile immunoassay diagnostic system and the S1 Panel assay for the detection of critical infections such as sepsis in the emergency department. The principal investigator of the study is Dr. Juan González del Castillo, Internal Medicine Specialist, Assistant Physician of the Emergency Service of HCSC and Coordinator of the Infections Group of the Spanish Society of Emergency Medicine (SEMES). The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
공시 • Jun 15Nanomix Corporation Receives IVDR Certification for the eLab AnalyzerNanomix Corporation announced that it has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer, part of the Nanomix eLab® system. The European Union (EU) IVDR replaces the legacy In Vitro Diagnostic Directive (IVDD) and was created to ensure a greater level of patient protection and regulation around the creation of in vitro diagnostic devices (IVDs). The Nanomix eLab® system is a rapid, easy-to-use, quantitative detection platform that performs a range of in vitro diagnostic assays. The platform consists of a hand-held analyzer and a disposable cartridge. The eLab System utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. The Nanomix eLab® system has received the CE marking in Europe.
공시 • May 27Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood SamplesNanomix Corporation announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample. The eLab S1 is currently marketed and CE marked for use with a plasma sample. The new authorization for a whole blood sample provides even faster results than the Company's earlier plasma-based panel by eliminating the step of first centrifuging blood to produce a plasma sample. Key Advantages: The ab b S1 assay panel is the first of its kind offering Procalcitonin(PCT), C-Reactive Protn (CRP) and LaLactate (LAC) for use on its testing device in emergency departments and decentralized healthcare environments,Faster time to results -- driving information within the initial clinical decision-making window,Increased accessibility and broader end-user market,Designed to help providers achieve better patient outcomes . The S1 Assay panel was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for LAC, CRP and PCT from a single plasma sample or venous whole blood sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The Nanomix eLab(R) system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab(R) offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. About Nanomix CorporationNanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nan mix eLab(R) System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company's products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix's first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.
공시 • May 18Nanomix Corporation announced delayed 10-Q filingOn 05/17/2022, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Mar 31Nanomix Corporation Appoints Vidur Sahney as Chief Operating OfficerNanomix Corporation announced the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assay development and quality. Most recently, Mr. Sahney served as Chief Operating Officer of ExThera Medical where he led the initiative to secure U.S. Food and Drug Administration (FDA) Emergency Use Authorization site clearance and CE mark for a Class III /PMA medical device, and commercialized the novel hemoperfusion filter used to treat blood stream infections and COVID-19 in Europe and the U.S.
공시 • Mar 30Nanomix Corporation announced delayed annual 10-K filingOn 03/29/2022, Nanomix Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Dec 09Nanomix Announces UK MHRA Registration for New Point of Care SystemNanomix Corporation announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge. The Nanomix eLab analyzer with S1 Panel Cartridge provides multiple host-response biomarker results that can assist healthcare providers in diagnosing and treating patients with critical infections, including sepsis.
공시 • Dec 02Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19Nanomix Corporation announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments. The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes. The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy.
공시 • Aug 17Boston Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.